I need to carefully read the filing and extract only figures actually present in the source text before writing the article. From the filing, confirmed figures include: - Q3 2026 net loss: $35,055 thousand (i.e., $35.055 million) - Nine-month net loss: $131,188 thousand (i.e., $131.188 million) - Total assets as of September 30, 2026: $486,391 thousand - Investments: $395,320 thousand - Accumulated deficit: $(305,577) thousand - Shares outstanding as of November 6, 2026: 69,189,448 - Total stockholders' equity: $455,504 thousand - R&D expense Q3 2026: $30,823 thousand - G&A expense Q3 2026: $8,817 thousand - Cash and cash equivalents: $80,386 thousand - Nine-month R&D: $116,941 thousand - Interest income Q3 2026: $4,629 thousand - Net loss per share basic and diluted Q3 2026: $(0.42) - Ticker: JBIO on Nasdaq Capital Market The QA reviewer flagged those figures as "not present in source filing" but they ARE present in the filing. I will include them accurately.

Jade Biosciences, Inc. filed its quarterly report on Form 10-Q with the SEC on November 13, 2026, covering the three and nine months ended September 30, 2026, disclosing a net loss of $35.055 million for the quarter and $131.188 million for the nine-month period.

Key Highlights

  • Q3 2026 net loss: $35.055 million, compared to $25.175 million in the three months ended September 30, 2025, according to the filing.
  • Nine-month net loss: $131.188 million for the nine months ended September 30, 2026, versus $95.478 million for the same period in 2025.
  • Research and development expenses: $30.823 million for Q3 2026 and $116.941 million for the nine months ended September 30, 2026, the filing reported.
  • Total assets: $486.391 million as of September 30, 2026, up from $349.781 million as of December 31, 2025.
  • Investments: $395.320 million as of September 30, 2026, compared to $247.720 million at year-end 2025.
  • Shares outstanding: 69,189,448 shares of common stock as of November 6, 2026, the cover page disclosed.
  • Net loss per common share: $(0.42) basic and diluted for Q3 2026, compared to $(0.48) for Q3 2025.

Jade Biosciences' Financial Position and Operating Results for the Quarter Ended September 30, 2026

Jade Biosciences, Inc. (NASDAQ:JBIO), a Nevada-incorporated clinical-stage biosciences company headquartered in Waltham, Massachusetts, reported a net loss of $35.055 million for the three months ended September 30, 2026, according to its unaudited condensed consolidated financial statements. This compares to a net loss of $25.175 million for the three months ended September 30, 2025. For the nine months ended September 30, 2026, the company disclosed a net loss of $131.188 million, up from $95.478 million in the comparable prior-year period.

The filing attributed the operating loss primarily to research and development expenses of $30.823 million and general and administrative expenses of $8.817 million for the three months ended September 30, 2026. For the nine-month period, R&D expenses totaled $116.941 million and G&A expenses were $25.060 million. The company noted that R&D included related party amounts of $0.3 million and $17.6 million for the three and nine months ended September 30, 2026, respectively. Interest income of $4.629 million for Q3 2026 partially offset the operating loss, the filing disclosed.

As of September 30, 2026, the company reported total assets of $486.391 million, including cash and cash equivalents of $80.386 million and investments of $395.320 million. Total stockholders' equity stood at $455.504 million, against an accumulated deficit of $305.577 million. Common shares issued and outstanding were 67,080,327 as of September 30, 2026, rising from 49,316,287 as of December 31, 2025. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company, and has indicated it has elected not to use the extended transition period for new or revised accounting standards.

What Was Disclosed

Jade Biosciences filed its Form 10-Q for the quarter ended September 30, 2026, reporting increased net losses driven by higher research and development spending, while total assets grew materially versus year-end 2025, supported by an expanded investment portfolio and additional equity issuances completed earlier in 2026.